Omeros Corporation (OMER) vs. The Competition Head to Head Contrast
Omeros Corporation (NASDAQ: OMER) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Omeros Corporation to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
Insider & Institutional Ownership
44.9% of Omeros Corporation shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 13.6% of Omeros Corporation shares are owned by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Omeros Corporation has a beta of 3.54, indicating that its share price is 254% more volatile than the S&P 500. Comparatively, Omeros Corporation’s peers have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.
Valuation and Earnings
This table compares Omeros Corporation and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Omeros Corporation||$53.60 million||-$48.15 million||-14.81|
|Omeros Corporation Competitors||$473.28 million||$171.89 million||-6.94|
Omeros Corporation’s peers have higher revenue and earnings than Omeros Corporation. Omeros Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Omeros Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Omeros Corporation Competitors||-10,710.84%||-348.48%||-43.36%|
This is a summary of current ratings and price targets for Omeros Corporation and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Omeros Corporation Competitors||1400||4543||12418||314||2.62|
Omeros Corporation currently has a consensus price target of $33.38, indicating a potential upside of 54.37%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.08%. Given Omeros Corporation’s stronger consensus rating and higher probable upside, analysts plainly believe Omeros Corporation is more favorable than its peers.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.